Protalix BioTherapeutics Inc. (PLX) Open at price of $2.28: A Brand-New Opportunity for Investors

Witnessing the stock’s movement on the chart, on May 25, 2023, Protalix BioTherapeutics Inc. (AMEX: PLX) had a quiet start as it plunged -8.33% to $2.09. During the day, the stock rose to $2.29 and sunk to $2.09 before settling in for the price of $2.28 at the close. Taking a more long-term approach, PLX posted a 52-week range of $1.00-$3.55.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 17.70%. Meanwhile, its Annual Earning per share during the time was 45.40%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 50.70%. This publicly-traded company’s shares outstanding now amounts to $57.48 million, simultaneously with a float of $41.75 million. The organization now has a market capitalization sitting at $143.44 million. At the time of writing, stock’s 50-day Moving Average stood at $2.38, while the 200-day Moving Average is $1.57.

It is imperative to bring your focus towards the efficiency factor of the conglomerate that has a total of 193 employees. It has generated 241,817 per worker during the last fiscal year. Meanwhile, its income per employee was -75,772. The stock had 11.87 Receivables turnover and 0.74 Total Asset turnover. For the Profitability, stocks gross margin was +58.87, operating margin was -27.32 and Pretax Margin of -30.22.

Protalix BioTherapeutics Inc. (PLX) Ownership Facts and Figures

Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Protalix BioTherapeutics Inc.’s current insider ownership accounts for 11.99%, in contrast to 19.60% institutional ownership. According to the most recent insider trade that took place on Jan 03, this organization’s Director bought 110,000 shares at the rate of 1.42, making the entire transaction reach 155,815 in total value, affecting insider ownership by 174,000.

Protalix BioTherapeutics Inc. (PLX) Earnings and Revenue Records

As on 12/30/2022, Multinational firm has announced its last quarter scores, in which it reported -$0.07 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.15) by $0.08. This company achieved a net margin of -31.33. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.

Protalix BioTherapeutics Inc.’s EPS increase for this current 12-month fiscal period is 50.70% and is forecasted to reach 0.63 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 25.00% through the next 5 years, which can be compared against the 45.40% growth it accomplished over the previous five years trading on the market.

Protalix BioTherapeutics Inc. (AMEX: PLX) Trading Performance Indicators

Let’s observe the current performance indicators for Protalix BioTherapeutics Inc. (PLX). It’s Quick Ratio in the last reported quarter now stands at 1.10. The Stock has managed to achieve an average true range (ATR) of 0.23. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.49.

In the same vein, PLX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.31, a figure that is expected to reach -0.15 in the next quarter, and analysts are predicting that it will be 0.63 at the market close of one year from today.

Technical Analysis of Protalix BioTherapeutics Inc. (PLX)

Going through the that latest performance of [Protalix BioTherapeutics Inc., PLX]. Its last 5-days volume of 2.07 million indicated improvement to the volume of 1.67 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 33.01% While, its Average True Range was 0.23.

Raw Stochastic average of Protalix BioTherapeutics Inc. (PLX) in the period of the previous 100 days is set at 34.68%, which indicates a major rise in contrast to 6.15% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 105.89% that was higher than 79.14% volatility it exhibited in the past 100-days period.